



## OPEN ACCESS

## EDITED AND REVIEWED BY

Wenzhi Yang,  
Tianjin University of Traditional  
Chinese Medicine, China

## \*CORRESPONDENCE

Xiaojuan Li,  
✉ lixiaojuan@jnu.edu.cn  
Dingkun Lin,  
✉ lindingkuntcm@126.com  
Jiake Xu,  
✉ jiake.xu@uwa.edu.au

<sup>†</sup>These authors have contributed equally  
to this work

RECEIVED 20 September 2023

ACCEPTED 27 November 2023

PUBLISHED 18 December 2023

## CITATION

He J, Chen K, Deng T, Xie J, Zhong K,  
Yuan J, Wang Z, Xiao Z, Gu R, Chen D, Li X,  
Lin D and Xu J (2023), Corrigendum:  
Inhibitory effects of Rhaponticin on  
osteoclast formation and resorption by  
targeting RANKL-induced NFATc1 and  
ROS activity.  
*Front. Pharmacol.* 14:1297863.  
doi: 10.3389/fphar.2023.1297863

## COPYRIGHT

© 2023 He, Chen, Deng, Xie, Zhong,  
Yuan, Wang, Xiao, Gu, Chen, Li, Lin and  
Xu. This is an open-access article  
distributed under the terms of the  
Creative Commons Attribution License  
(CC BY). The use, distribution or  
reproduction in other forums is  
permitted, provided the original author(s)  
and the copyright owner(s) are credited  
and that the original publication in this  
journal is cited, in accordance with  
accepted academic practice. No use,  
distribution or reproduction is permitted  
which does not comply with these terms.

# Corrigendum: Inhibitory effects of Rhaponticin on osteoclast formation and resorption by targeting RANKL-induced NFATc1 and ROS activity

Jianbo He<sup>1,2†</sup>, Kai Chen<sup>2†</sup>, Tiancheng Deng<sup>1</sup>, Jiewei Xie<sup>1</sup>,  
Kunjing Zhong<sup>1</sup>, Jinbo Yuan<sup>2</sup>, Ziyi Wang<sup>2</sup>, Zhifeng Xiao<sup>1</sup>,  
Ronghe Gu<sup>2,3</sup>, Delong Chen<sup>4</sup>, Xiaojuan Li<sup>5\*</sup>, Dingkun Lin<sup>1\*</sup> and  
Jiake Xu<sup>2\*</sup>

<sup>1</sup>The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Zhuhai, China, <sup>2</sup>School of Biomedical Sciences, University of Western Australia, Perth, WA, Australia, <sup>3</sup>Department of Orthopedics, First People's Hospital of Nanning, Fifth Affiliated Hospital of Guangxi Medical University, Nanning, China, <sup>4</sup>The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China, <sup>5</sup>Formula-Pattern Research Center, School of Traditional Chinese Medicine, Jinan University, Guangzhou, China

## KEYWORDS

osteoclast, NFATc1, ROS, rhaponticin, bone

## A Corrigendum on

### Inhibitory effects of Rhaponticin on osteoclast formation and resorption by targeting RANKL-induced NFATc1 and ROS activity


by He J, Chen K, Deng T, Xie J, Zhong K, Yuan J, Wang Z, Xiao Z, Gu R, Chen D, Li X, Lin D and Xu J (2021). *Front. Pharmacol.* 12:645140. doi: 10.3389/fphar.2021.645140

In the published article, there was an error in **Figure 3A** about the 50  $\mu$ M TRAcP picture as published. Two pictures were taken from the same cell culture well with 25  $\mu$ M treatment, and partially overlapped images were obtained during photo taking, because both were from the same well. However, one image was placed as a 50  $\mu$ M group, which occurred during the process of PowerPoint figure preparation due to an oversight. The corrected **Figure 3** appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.



**FIGURE 3** RH attenuated osteoclast hydroxyapatite resorption and osteoclast-specific genes expression. (A) Representative images of the resorption on hydroxyapatite-coated plates and TRAcP staining after treatment of RH for 48 hr. (B) Quantification of TRAcP-positive osteoclasts numbers per well (n = 3). (C) Quantification of resorption area on hydroxyapatite surface per osteoclast (n = 3). (D–G) PCR results of osteoclast-specific genes *Nfatc1*, *c-Fos*, *Ctsk*, and *Atp6v0d2*. Gene expression levels were standardized to *Hprt* expression. \*p < 0.05, \*\*p < 0.01 relative to RANKL-induced control group. Scale bar = 200 µm.